<p>Asymchem (06821.HK) announced its full-year results for the year ending December last year, with a revenue of RMB 6.67 billion, an increase of 14.9% year-on-year. The net profit was RMB 1.133 billion, up 19.3% year-on-year; earnings per share were RMB 3.16. A final dividend of RMB 1.3 was declared, compared to RMB 1.1 in the same period last year</p>

159849

159837

588130

<p>Asymchem announced its full-year results for the year ending last December, with a revenue of RMB 6.67 billion, an increase of 14.9% year-on-year. The net profit was RMB 1.133 billion, up 19.3% year-on-year; earnings per share were RMB 3.16. A final dividend of RMB 1.3 was declared, compared to RMB 1.1 in the same period last year</p>

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Asymchem

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

"Performance" Asymchem's net profit last year was RMB 1.133 billion, an increase of 19.3%, with a final dividend of RMB 1.3